Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Morbidity Study

Trial Profile

Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Morbidity Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Acute sinusitis; Asthma; Bacterial infections; Cholera; Community-acquired pneumonia; Cystic fibrosis; Gastroparesis; Otitis media; Pelvic inflammatory disorders; Pertussis; Sexually transmitted infections; Typhoid
  • Focus Therapeutic Use
  • Acronyms MORDOR2
  • Most Recent Events

    • 15 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 15 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
    • 30 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top